SCA
VRTX icon

Snowden Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Snowden Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
4,230
+397
+10% +$176K 0.05% 349
2026
Q1 		$1.71M Sell
3,833
-85
-2% -$39.6K 0.05% 373
2025
Q4 		$1.78M Buy
3,918
+87
+2% +$37.5K 0.05% 361
2025
Q3 		$1.5M Sell
3,831
-126
-3% -$52.7K 0.04% 399
2025
Q2 		$1.76M Sell
3,957
-640
-14% -$295K 0.05% 340
2025
Q1 		$2.23M Sell
4,597
-143
-3% -$66.6K 0.07% 273
2024
Q4 		$1.91M Sell
4,740
-6,647
-58% -$3.08M 0.06% 315
2024
Q3 		$5.3M Sell
11,387
-2,606
-19% -$1.25M 0.16% 153
2024
Q2 		$6.56M Sell
13,993
-354
-2% -$154K 0.2% 119
2024
Q1 		$6M Buy
14,347
+250
+2% +$106K 0.19% 134
2023
Q4 		$5.74M Buy
14,097
+539
+4% +$199K 0.22% 118
2023
Q3 		$4.71M Sell
13,558
-84
-0.6% -$29.4K 0.2% 142
2023
Q2 		$4.8M Buy
13,642
+364
+3% +$123K 0.17% 157
2023
Q1 		$4.18M Sell
13,278
-69
-0.5% -$20.7K 0.16% 162
2022
Q4 		$3.85M Buy
13,347
+8,535
+177% +$2.6M 0.16% 156
2022
Q3 		$1.39M Sell
4,812
-323
-6% -$92.9K 0.06% 336
2022
Q2 		$1.45M Buy
5,135
+1,193
+30% +$319K 0.06% 323
2022
Q1 		$1.03M Buy
3,942
+3,573
+968% +$848K 0.04% 424
2021
Q4 		$81K Sell
369
-3,515
-90% -$684K ﹤0.01% 905
2021
Q3 		$705K Buy
3,884
+2,202
+131% +$430K 0.04% 450
2021
Q2 		$339K Buy
1,682
+533
+46% +$111K 0.02% 669
2021
Q1 		$247K Buy
1,149
+202
+21% +$44.4K 0.01% 697
2020
Q4 		$224K Buy
947
+98
+12% +$22.5K 0.01% 606
2020
Q3 		$231K Buy
849
+2
+0.2% +$552 0.02% 517
2020
Q2 		$246K Sell
847
-24
-3% -$6.51K 0.02% 497
2020
Q1 		$207K Buy
+871
New +$200K 0.02% 490

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Snowden Capital Advisors's VRTX Position: Q2 2026 in Review

Snowden Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, buying an estimated $176K and bringing the position to 4,230 shares worth $2.1M. The position accounts for 0.05% of the portfolio, ranked #349.

Snowden Capital Advisors first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.56M in Q2 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Snowden Capital Advisors held 4,230 shares of Vertex Pharmaceuticals worth $2.1M as of Q2 2026.
  • Snowden Capital Advisors bought 397 Vertex Pharmaceuticals shares in Q2 2026, an estimated $176K.
  • Vertex Pharmaceuticals made up 0.05% of Snowden Capital Advisors's portfolio in Q2 2026, its #349 holding.
  • Snowden Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Snowden Capital Advisors's Vertex Pharmaceuticals position peaked at $6.56M in Q2 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.